Last update: Aug. 28, 2020
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Losartan Potassium in other languages or writings:
Losartan Potassium belongs to this group or family:
Main tradenames from several countries containing Losartan Potassium in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 33 | % |
Molecular weight | 461 | daltons |
Protein Binding | 99 | % |
VD | 0,5 | l/Kg |
Tmax | 1 - 3 | hours |
T1/2 | 2 - 9 | hours |
Write to us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche de Euskadi
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is an angiotensin II receptor antagonist with antihypertensive activity.
It is indicated in the treatment of hypertension and in heart failure.
Oral administration once a day
At latest update, relevant published data on excretion into breast milk were not found.
A high protein-binding capacity makes excretion into breast milk unlikely. In addition, a low oral bioavailability makes difficult the absorption towards the infant's plasma from ingested milk (Kearney 2018), except in prematures or newborns who may show an increased absorption.
Until more data on this medication is available, safer alternative drugs are preferred (Rowe 2013), especially in premature babies or during the neonatal period.